多西他赛、顺铂和氟尿嘧啶同期放化疗治疗未行声带固定的 T3N0 声门型喉癌。
Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil for T3 N0 Glottic Carcinoma Without Vocal Cord Fixation.
机构信息
Department of Radiation Oncology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
Department of Radiation Oncology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
出版信息
Anticancer Res. 2022 Jan;42(1):205-209. doi: 10.21873/anticanres.15474.
BACKGROUND/AIM: We retrospectively evaluated the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin, and 5-fluorouracil (TPF) for T3 N0 glottic carcinoma without vocal cord fixation.
PATIENTS AND METHODS
Twenty-five patients underwent TPF-CCRT without elective nodal irradiaion (ENI). After the RT of 40 Gy, five patients (20%) without tumor regression underwent surgery. Others underwent RT with a median total dose of 66 Gy.
RESULTS
Of the five patients who underwent surgery after the RT of 40 Gy, two showed residual carcinoma pathologically and the other three were confirmed to have complete pathological response to the treatment. The 5-year local control rate was 87%. No patients exhibited regional failure. No acute toxicities of grade 5 or late toxicities ≥grade 3 were observed.
CONCLUSION
TPF-CCRT provides excellent tumor control with acceptable toxicities. CCRT while omitting ENI is a reasonable approach for T3 N0 glottic carcinoma without vocal cord fixation.
背景/目的：我们回顾性评估了多西他赛、顺铂和 5-氟尿嘧啶（TPF）联合同期放化疗（CCRT）治疗 T3N0 声带固定型声门型喉癌的疗效和毒性。
患者和方法
25 例患者接受 TPF-CCRT 治疗，不进行选择性淋巴结照射（ENI）。在 40 Gy 的放疗后，5 名患者（20%）没有肿瘤消退，接受了手术。其他患者接受中位总剂量为 66 Gy 的放疗。
结果
在 40 Gy 放疗后接受手术的 5 名患者中，2 名患者病理检查显示有残余癌，3 名患者病理检查显示对治疗有完全的病理反应。5 年局部控制率为 87%。无区域性失败病例。无 5 级急性毒性或≥3 级迟发性毒性。
结论
TPF-CCRT 提供了极好的肿瘤控制效果，毒性可接受。对于 T3N0 声带固定型声门型喉癌，省略 ENI 的 CCRT 是一种合理的方法。
Zotero 插件